AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01405898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beetroot juice
Description: Beetroot juice 4 weeks 250ml daily
Study NCT01405898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-free beetroot juice
Description: Nitrate-free beetroot juice 4 weeks 250ml daily
Study NCT02141906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncozene-DEB-TACE
Description: ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
Study NCT02985112 — intervention group
Intervention type: DEVICE
Intervention: FFR and IVUS-NIRS
Study NCT01839916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given IV
Study NCT01839916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04014218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation Sedation
Description: Inhalation Sedation by Administration of Sevoflurane
Study NCT04014218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Sedation
Description: Intravenous Sedation by Administration of Propofol
Study NCT04621058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: In case of Vitamin D levels \<30 or 40ng/ml patients will take vitamin D supplements.
Study NCT06775990 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Children were not given any medication in the study. Peripheral blood samples from the children were collected, centrifuged and stored in the biochemistry laboratory in deep freezers at -80 degree celcius. From stored serum samples leptin, leptin receptor (LEPR), ghrelin, acylated ghrelin, deacylated ghrelin, ghrelin receptor (GHSR), kisspeptin (KISS1), kisspeptin receptor (KISS1R), preptin, Peroxisome proliferator-activated receptor gamma (PPAR γ), nod-like receptor pyrin domain-containing 3 (NLRP3), interleukin-18 (IL-18) levels were determined by ELISA in thirty obese and thirty healthy children.
Study NCT04621058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo capsules exactly the same as the above, but without the active component.
Study NCT04094961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Oral, administered four times per cycle
Study NCT04094961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral, administered 14 times per cycle
Study NCT04094961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral, fixed dose administered 8 times per cycle
Study NCT03016091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti PD-L1
Study NCT04531722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative brain microdialysis
Description: Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe.
Study NCT04371237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression sleeve
Description: From foot to hip/groin on both legs with only 1 leg connected to pneumatic pump for 1 hour
Study NCT04371237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Custom leg garment with one leg heated by circulating hot water approx 40 degrees C, the other leg approx 32 degrees C (thermoneutral) for 1 hour
Study NCT04371237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycogen-depleting exercise session
Description: Prolonged intermittent high intensity running (LIST protocol)
Study NCT04371237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrient Intake (beverage)
Description: Post-exercise, all participants will receive a beverage containing 1.0 g/kg carbohydrate and 0.3 g/kg protein from the mixture of Gatorade Recover Protein Shake and Gatorade Thirst Quencher
Study NCT04371237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skeletal muscle biopsy
Description: Vastus lateralis muscle in the lower thigh will be obtained by the percutaneous needle technique
Study NCT04710069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POINT
Description: Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.
Study NCT00507260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Record
Description: A record of the amount and kind of food and drink you intake will be completed.
Study NCT00507260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Consults
Description: Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
Study NCT03284853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil/Latanoprost 0.02%/0.005%
Description: Topical sterile ophthalmic solution
Study NCT03284853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GANFORT®
Description: Topical sterile ophthalmic solution
Study NCT03863977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
Study NCT03863977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.
Study NCT02790697 — intervention group
Intervention type: OTHER
Intervention: Indirect calorimetry
Description: Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
Study NCT03642847 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: 13 valent Pneumococcal Conjugate
Study NCT03642847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multivalent pneumococcal conjugate formulation 1
Description: multivalent pneumococcal conjugate formulation 1
Study NCT03642847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multivalent pneumococcal conjugate formulation 2
Description: multivalent pneumococcal conjugate formulation 2
Study NCT01757951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unimalleolar fixation
Description: Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
Study NCT01757951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bimalleolar fixation
Description: Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
Study NCT03437889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Stimulus (Ice)
Description: The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen between 10 and 30 minutes after the epidural catheter is inserted.
Study NCT02774811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin analogue
Description: Topical therapy
Study NCT02774811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasy
Description: Laser therapy into drainage angle
Study NCT02774811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Study NCT02086318 — intervention group
Intervention type: OTHER
Intervention: OvAge assessment
Description: Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and Estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle. Evaluation can be repeated after every kind of intervention regarding ovaries, both medical or surgical. Evaluation can be repeated also at interval of 3-6-12 months in order to study the modification of ovarian age when time passes.
Study NCT02793739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid filler injection
Description: Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
Study NCT01475305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
Study NCT01475305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
Study NCT02385058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
Study NCT02385058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinfamide
Description: Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
Study NCT02385058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet orally once starting on Day 21.
Study NCT02294357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT02294357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: If the patient was receiving steroids at the equivalent of > 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
Study NCT02294357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: f the patient was receiving prednisone, at the equivalent of > 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
Study NCT02294357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: If the patient was receiving methylprednisolone at the equivalent of > 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
Study NCT02294357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
Study NCT02294357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: administered PO at 4mg daily on days 1-21 of a 28 day cycle
Study NCT01860599 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: 150 minutes of moderate exercise per week
Study NCT04041921 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Study NCT04041921 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Grafting
Study NCT01860599 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Without exercise
Description: Pre-study activity level (i.e. no exercise)
Study NCT03520738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples on an empty stomach
Study NCT03520738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urinary samples
Description: first urinary in the morning
Study NCT04041921 — intervention group
Intervention type: DRUG
Intervention: Medical treatment
Study NCT00960804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: IV, 5 mg dose, q 8 weeks, for up to 80 weeks
Study NCT00960804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: IV, 10 mg dose, q 8 weeks, for up to 80 weeks
Study NCT00960804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV, q 8 weeks, for up to 80 weeks
Study NCT04491461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbal tea blend
Description: 1 cup of freshly brewed tea from an herbal tea blend.
Study NCT04491461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Warm water
Description: 1 cup of warm water
Study NCT00847418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine hydrochloride
Study NCT01775423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Study NCT02285296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized support program
Description: interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up
Study NCT04486625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam-Avibactam
Description: 500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
Study NCT04486625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam-Avibactam
Description: 675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours
Study NCT02422576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cinnamon extract
Description: acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
Study NCT02422576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lemon extract
Description: acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
Study NCT02422576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lemon extract plus eucalyptus extract
Description: acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
Study NCT02422576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thicken Up clear: TUC
Study NCT01205022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01205022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01205022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01205022 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01205022 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Description: Given IV
Study NCT01205022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02958605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone apps
Description: If already own a smartphone application dedicated to calculate medication dosage for children, the participant will be allowed to use his/her own application. Otherwise, the resident will be offered to chose among a list of applications paid by the research team (PediSafe, PediStat, Palm Pedi, Safedose, EZdrip peds). He/she will be instructed to practice with a few time at home before doing the simulations.
Study NCT02958605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handbook
Description: Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
Study NCT02701881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long stenting using drug-eluting stent (Zilver PTX)
Description: Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty
Study NCT02701881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spot stenting using drug-eluting stent (Zilver PTX)
Description: Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion
Study NCT03744013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fortiva® 1mm
Description: Post mastectomy immediate reconstruction
Study NCT03576274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Enhanced Home Exercise (TEHE)
Description: A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.
Study NCT03774615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol 30 mg (Feraccru®)
Description: Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
Study NCT03576274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Auricular Point Acupressure (APA)
Description: A non invasive complementary method to provide pressure on the ear points.
Study NCT03576274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure (APA)
Description: A non invasive complementary method to provide pressure on the ear points.
Study NCT03576274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness body scan (MBI)
Description: The open, nonjudgmental attention to move one's attention calmly to the different part of the body
Study NCT01517308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha 2a + ribavirin
Description: Comparison of different duration of drugs (48 weeks vs. 24 weeks)
Study NCT01517308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a + ribavirin
Description: Comparison of different duration of drugs (48 weeks vs. 24 weeks)
Study NCT03466047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein stomach
Description: encapsulated protein stomach
Study NCT03466047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein distal small intestine
Description: encapsulated protein distal small intestine
Study NCT03249168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg
Description: tablet
Study NCT03249168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT02953015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manipulative articulatory (ART) and myofascial techniques
Description: Three manipulative articulatory (ART) and myofascial techniques will be performed to improve cervical and thoracic spine joint mobility and reducing soft tissue stiffness in the cervico-thoracic spine. ART technique is a low velocity to high amplitude technique where each joint is carried through its full motion to increase range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier. Myofascial technique is directed at the muscle and fascia treatment. It engages continual palpatory feedback to achieve release of myofascial tissues. During each treatment session, each technique will be carried out for 10 minutes including 2 minutes of resting.